Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

712
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
712
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

880
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
880
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

625
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
625
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

1.0K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.0K
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

524
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
524
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

564
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
564

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Heat-Inactivated Two-Strain <i>Lacticaseibacillus paracasei</i> Fermented Milk as a Postbiotic for Functional Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial.

Nutrients·2026
Same author

Daily supplementation with egg yolk lipids from two eggs alleviated cognitive impairment in 5 × FAD mice by restoring neuronal and synaptic function and regulating gut microbiota.

Food & function·2026
Same author

Recent advances in nanofiber-based probiotic delivery systems.

Critical reviews in food science and nutrition·2026
Same author

Comparative Mechanisms of Different <i>Bifidobacteria</i> in Combating Pathogen Infection and Prolonging the Lifespan in <i>Caenorhabditis elegans</i>.

Microorganisms·2025
Same author

Untargeted Metabolomics Reveals Shared and Unique Metabolites in <i>Bifidobacterium</i> and <i>Lactobacillus</i> Derived Postbiotics.

Journal of agricultural and food chemistry·2025
Same author

PEMT-mediated phospholipid imbalance promotes age-associated metabolic dysfunction-associated steatotic liver disease progression.

The FEBS journal·2025

Related Experiment Video

Updated: Jan 15, 2026

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.0K

Modulation of Intestinal Smooth Muscle Cell Function by BL-99 Postbiotics in Functional Constipation.

Wen Zhao1, Mingkun Liu2, Hanglian Lan3

  • 1Key Laboratory of Functional Dairy, Department of Nutrition and Health, China Agricultural University, Beijing 100190, China.

Foods (Basel, Switzerland)
|October 16, 2025
PubMed
Summary

Postbiotics from Bifidobacterium animalis BL-99 effectively relieve constipation by improving gut motility and hydration. Key peptides, Glu-Val and Glu-Leu, were identified as active components regulating intestinal muscle cell function.

Keywords:
Bifidobacterium animalis subsp lactis BL-99functional constipationglutamate metabolismpostbioticssmooth muscle cells

More Related Videos

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

941
Gastrointestinal Motility Monitor GIMM
08:15

Gastrointestinal Motility Monitor GIMM

Published on: December 1, 2010

31.5K

Related Experiment Videos

Last Updated: Jan 15, 2026

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.0K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

941
Gastrointestinal Motility Monitor GIMM
08:15

Gastrointestinal Motility Monitor GIMM

Published on: December 1, 2010

31.5K

Area of Science:

  • Microbiology
  • Gastroenterology
  • Functional Foods

Background:

  • Postbiotics are gaining interest for food applications and health benefits.
  • Their mechanisms for alleviating constipation are not fully understood.
  • Bifidobacterium animalis subsp. lactis BL-99 (BL-99) derived postbiotics were investigated.

Purpose of the Study:

  • To investigate the effects of BL-99 postbiotics on functional constipation (FC).
  • To elucidate the underlying mechanisms of action.
  • To identify specific bioactive components responsible for the effects.

Main Methods:

  • In vivo and in vitro models were used to assess FC.
  • Intestinal motility, fecal water content, and smooth muscle cell (SMC) apoptosis were measured.
  • Contractile responses and proliferation of intestinal SMCs were analyzed.
  • Untargeted metabolomics identified bioactive peptides.

Main Results:

  • BL-99 and its postbiotics significantly alleviated FC symptoms.
  • Intestinal motility and fecal water content were enhanced.
  • Intestinal muscular layer thickness increased, and SMC apoptosis decreased.
  • BL-99 postbiotics promoted SMC proliferation and enhanced contractile responses.
  • Glu-Val and Glu-Leu peptides were identified as key active components.

Conclusions:

  • BL-99 postbiotics demonstrate significant efficacy in ameliorating functional constipation.
  • These postbiotics act by enhancing intestinal motility and regulating intestinal SMC function.
  • The identified peptides Glu-Val and Glu-Leu are crucial for the observed effects.
  • BL-99 postbiotics represent a promising functional food ingredient for constipation management.